Histopathological and molecular analysis of idiopathic pulmonary fibrosis lungs from patients treated with pirfenidone or nintedanib
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
Aims: The objective of this study was to quantify the impact of pirfenidone or nintedanib treatment on lung histopathology and molecular mediators of fibrosis in patients with idiopathic pulmonary fibrosis (IPF). Methods and results: We collected lung tissue from IPF patients at the time of lung transplantation. Histopathological changes were quantified using a blinded scoring method. Proteins associated with senescence or active TGF‐β were quantified in lung tissues by immunoblot and immunostaining. Histopathological quantification showed similar amounts of dense collagen fibrosis, fibroblast foci and alveolar macrophages in untreated or pirfenidone‐ or nintedanib‐treated IPF patients. There was less diffuse alveolar damage and organising pneumonia in pirfenidone‐treated IPF patients. Lungs of nintedanib‐treated patients had a trend towards less lymphocytic interstitial infiltration. There was no difference in expression of p‐SMAD 3, p21 or p16 in the lungs of untreated, pirfenidone‐ or nintedanib‐treated IPF patients. Alveolar epithelial cells, but not fibroblast foci, were immunoreactive to p16. Pirfenidone or nintedanib treatment did not inhibit activation of senescence programming in cultured lung epithelial cells mediated by hydrogen peroxide. Conclusion: Pirfenidone and nintedanib do not modulate expression of senescence markers, levels of p‐SMAD 3 or the amount of fibrosis in IPF lungs. Treated patients have less histopathological evidence of acute lung injury at the time of lung transplantation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654 · cited 2×
“Nintedanib is a tyrosine kinase inhibitor that targets multiple kinases including (in order of potency) vascular endothelial growth factor receptor (VEGFR), lymphocyte-specific protein tyrosine kinase (LCK), fibroblast growth factor receptor (FGFR) and plateletderived growth factor receptor (PDGFR).(3,23) In-vitro exp…”
BackgroundA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
The Achilles' heel of senescent cells: from transcriptome to senolytic drugs
Zhu, Y., Tchkonia, T., Pirtskhalava, T., Gower, A. C., Ding, H., Giorgadze, N., Palmer, A. K., Ikeno, Y., Hubbard, G. B., Lenburg, M., et al. (2015) · Aging Cell · doi:10.1111/acel.12344 · Cited by 2,584 · cited 1×
“Senolytics are drugs that selectively kill senescent cells.(12) ABT-263, a senolytic drug, can reverse ionising radiation-induced pulmonary fibrosis.”
BackgroundIncidence and Prevalence of Idiopathic Pulmonary Fibrosis
Raghu, G., Weycker, D., Edelsberg, J., Bradford, W. Z., & Oster, G. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-163oc · Cited by 1,310 · cited 1×
“The prevalence of IPF increases with age and is rare in patients younger than age 50 years.(1,5) In Address for correspondence: P J Wolters, University of California, San Francisco, Box 0111, San Francisco, CA 94143-0111, USA.”
BackgroundBIBF 1120: Triple Angiokinase Inhibitor with Sustained Receptor Blockade and Good Antitumor Efficacy
Hilberg, F., Roth, G. J., Krssak, M., Kautschitsch, S., Sommergruber, W., Tontsch-Grunt, U., Garin-Chesa, P., Bader, G., Zoephel, A., Quant, J., et al. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-6307 · Cited by 1,056 · cited 1×
“Nintedanib is a tyrosine kinase inhibitor that targets multiple kinases including (in order of potency) vascular endothelial growth factor receptor (VEGFR), lymphocyte-specific protein tyrosine kinase (LCK), fibroblast growth factor receptor (FGFR) and plateletderived growth factor receptor (PDGFR).(3,23) In-vitro exp…”
BackgroundShort telomeres are a risk factor for idiopathic pulmonary fibrosis
Alder, J. K., Chen, J. J.-L., Lancaster, L., Danoff, S., Su, S.-C., Cogan, J. D., Vulto, I., Xie, M., Qi, X., Tuder, R. M., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0804280105 · Cited by 805
Roos, C. M., Zhang, B., Palmer, A. K., Ogrodnik, M. B., Pirtskhalava, T., Thalji, N. M., Hagler, M., Jurk, D., Smith, L. A., Casaclang‐Verzosa, G., et al. (2016) · Aging Cell · doi:10.1111/acel.12458 · Cited by 738
Stuart, B. D., Lee, J. S., Kozlitina, J., Noth, I., Devine, M. S., Glazer, C. S., Torres, F., Kaza, V., Girod, C. E., Jones, K. D., et al. (2014) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(14)70124-9 · Cited by 310 · cited 1×
“Consistent with an ageing theory, IPF patients with short telomeres in peripheral blood leucocytes have worse survival.(7) Short telomeres are found in lung epithelial cells of most IPF patients(8,9) where they are associated with senescent epithelial cells,(10) which is sufficient to cause lung remodelling and fibros…”
MethodSelf-citationTelomere dysfunction in alveolar epithelial cells causes lung remodeling and fibrosis
Naikawadi, R. P., Disayabutr, S., Mallavia, B., Donne, M. L., Green, G., La, J. L., Rock, J. R., Looney, M. R., & Wolters, P. J. (2016) · JCI Insight · doi:10.1172/jci.insight.86704 · Cited by 267 · cited 1×
“Short telomeres are found in lung epithelial cells of most IPF patients(8,9) where they are associated with senescent epithelial cells,(10) which is sufficient to cause lung remodelling and fibrosis in mouse models of lung fibrosis.(11) Senolytics are drugs that selectively kill senescent cells.”
BackgroundSelf-citationNovel mechanisms for the antifibrotic action of nintedanib
Rangarajan, S., Kurundkar, A., Kurundkar, D., Bernard, K., Sanders, Y. Y., Ding, Q., Antony, V. B., Zhang, J., Zmijewski, J., & Thannickal, V. J. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2014-0445oc · Cited by 238
Time for a change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic?
Wolters, P. J., Blackwell, T. S., Eickelberg, O., Loyd, J. E., Kaminski, N., Jenkins, G., Maher, T. M., Molina-Molina, M., Noble, P. W., Raghu, G., et al. (2018) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(18)30007-9 · Cited by 196
Self-citationDisayabutr, S., Kim, E. K., Cha, S.-I., Green, G., Naikawadi, R. P., Jones, K. D., Golden, J. A., Schroeder, A., Matthay, M. A., Kukreja, J., et al. (2016) · PLOS ONE · doi:10.1371/journal.pone.0158367 · Cited by 136
Self-citationAge-driven developmental drift in the pathogenesis of idiopathic pulmonary fibrosis
Selman, M., López-Otín, C., & Pardo, A. (2016) · European Respiratory Journal · doi:10.1183/13993003.00398-2016 · Cited by 122 · cited 8×
“Pirfenidone and nintedanib, referred to colloquially as ‘antifibrotic medications’, have recently been approved for treatment of IPF.”
BackgroundInfluential
Research works printed but not linked: 12
- 10.1146/annurev-pathol-012513-104706 · DOI · Paper page
- 10.1056/NEJMra0903373 · DOI · Paper page
- 10.1164/rccm.201406-1162OC · DOI · Paper page
- 10.1016/j.ijrobp.2017.02.216 · DOI · Paper page
- 10.1183/13993003.02367-2016 · DOI · Paper page
- 10.1164/rccm.2009-040GL · DOI · Paper page
- 10.1016/S2213-2600(17)30216-3 · DOI · Paper page
- 10.1002/path.826 · DOI · Paper page
- 10.1093/toxsci/kfg167 · DOI
- 10.1016/j.jtcvs.2005.04.012 · DOI
- 10.1183/13993003.00026-2015 · DOI · Paper page
- 10.1165/rcmb.2016-0217OC · DOI · Paper page
Cited by
Idiopathic Pulmonary Fibrosis: An Update on Pathogenesis
Mei, Q., Liu, Z., Zuo, H., Yang, Z., & Qu, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.797292 · Cited by 360
Pirfenidone: Molecular mechanisms and potential clinical applications in lung disease
Ruwanpura, S. M., Thomas, B. J., & Bardin, P. G. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0328tr · Cited by 317
Nambiar, A., Kellogg, D., Justice, J., Goros, M., Gelfond, J., Pascual, R., Hashmi, S., Masternak, M., Prata, L., LeBrasseur, N., et al. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104481 · Cited by 298
Pirfenidone anti-fibrotic effects are partially mediated by the inhibition of MUC1 bioactivation
Ballester, B., Milara, J., & Cortijo, J. (2020) · Oncotarget · doi:10.18632/oncotarget.27526 · Cited by 43
“Nevertheless, it has been observed no difference in expression of p21 or p16 in the lungs of untreated or pirfenidone-treated IPF patients [37].”
BackgroundEvaluation of Pirfenidone and Nintedanib in a Human Lung Model of Fibrogenesis
Roach, K., Castells, E., Dixon, K., Mason, S., Elliott, G., Marshall, H., Poblocka, M., Macip, S., Richardson, M., Khalfaoui, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.679388 · Cited by 39
Metadata
- Authors
- Zhang, Y., Jones, K. D., Achtar‐Zadeh, N., Green, G., Kukreja, J., Xu, B., & Wolters, P. J.
- Venue
- Histopathology
- Publisher
- Wiley
- Published
- 2018-11-11
- Volume
- 74
- Issue
- 2
- Pages
- 341-349
- ISSN
- 0309-0167 (ISSN-L)
- 1365-2559
- OpenAlex
- W2889209098
- Cited by
- 26
- References
- 13
- FWCI
- 2.71
- Type
- journal article
- Language
- en
- Open access
- closed
- Funders
- National Natural Science Foundation of China (81570055)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.